Trust Co. of Toledo NA OH raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 7.4% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 27,939 shares of the company’s stock after buying an additional 1,917 shares during the period. Trust Co. of Toledo NA OH’s holdings in Eli Lilly and were worth $2,300,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Cullinan Associates Inc. raised its stake in shares of Eli Lilly and by 0.6% during the 2nd quarter. Cullinan Associates Inc. now owns 31,967 shares of the company’s stock valued at $2,631,000 after buying an additional 200 shares during the last quarter. Beutel Goodman & Co Ltd. raised its stake in shares of Eli Lilly and by 13.8% during the 2nd quarter. Beutel Goodman & Co Ltd. now owns 2,564,357 shares of the company’s stock valued at $162,556,000 after buying an additional 311,417 shares during the last quarter. Stokes & Hubbell Capital Management LLC purchased a new position in shares of Eli Lilly and during the 2nd quarter valued at about $300,000. Pennsylvania Trust Co raised its stake in shares of Eli Lilly and by 78.7% during the 2nd quarter. Pennsylvania Trust Co now owns 14,020 shares of the company’s stock valued at $1,154,000 after buying an additional 6,175 shares during the last quarter. Finally, Gateway Investment Advisers LLC raised its stake in shares of Eli Lilly and by 3.0% during the 2nd quarter. Gateway Investment Advisers LLC now owns 570,790 shares of the company’s stock valued at $46,976,000 after buying an additional 16,549 shares during the last quarter. Institutional investors and hedge funds own 75.72% of the company’s stock.

Several brokerages recently weighed in on LLY. UBS AG lowered Eli Lilly and to a “hold” rating and set a $85.00 price target for the company. in a research note on Wednesday, July 26th. Jefferies Group LLC restated a “buy” rating and issued a $93.00 price target on shares of Eli Lilly and in a research note on Thursday, June 22nd. Berenberg Bank restated a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a research note on Friday, August 4th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price target for the company in a research note on Monday, July 17th. Finally, Piper Jaffray Companies restated an “overweight” rating and issued a $105.00 price target (up previously from $103.00) on shares of Eli Lilly and in a research note on Friday, September 8th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $88.27.

Shares of Eli Lilly and Company (NYSE:LLY) traded up 0.70% on Friday, hitting $83.91. The stock had a trading volume of 3,148,723 shares. The company’s 50 day moving average is $80.84 and its 200 day moving average is $82.02. The stock has a market cap of $88.53 billion, a PE ratio of 36.31 and a beta of 0.34. Eli Lilly and Company has a one year low of $64.18 and a one year high of $86.72.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same quarter last year, the business earned $0.86 earnings per share. Eli Lilly and’s revenue was up 7.8% compared to the same quarter last year. Equities research analysts predict that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/24/trust-co-of-toledo-na-oh-buys-1917-shares-of-eli-lilly-and-company-lly.html.

In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the sale, the insider now owns 124,049,283 shares in the company, valued at $10,307,254,924.47. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last 90 days, insiders have sold 590,000 shares of company stock worth $48,551,300. 0.20% of the stock is owned by company insiders.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.